Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q1 2022 · 10-Q
Revenue$1.60M$1.60M−32.0% vs Q1 2021 Net Income-$1.03M-$1.03MN/M vs Q1 2021 EPS Diluted-$0.22-$0.22N/M vs Q1 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flow-$879,439N/M Free Cash Flowderived-$880,830— Margins · derivedGross margin-10.6%−22.1 pt vs Q1 2021
Operating margin-56.8%−27.3 pt vs Q1 2021
Net margin-64.2%−31.6 pt vs Q1 2021
ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end